MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala

Neurodegenerative Diseases

Volumn 2, Issue 1, 2005, Pages 44-48

  Von Bohlen Und Halbach, Oliver ^a   Schober, Andreas ^a   Hertel, Richard ^a   Unsicker, Klaus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Immunohistochemistry; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROCHEMISTRY; EMOTION; EVALUATION; IMMUNOCOMPETENT CELL; LIMBIC SYSTEM; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMYGDALA; ANIMALS; AXONS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROTOXINS; PARKINSONIAN DISORDERS; TYROSINE 3-MONOOXYGENASE;

EID: 23844443156     PISSN: 16602854     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086430     Document Type: Article

References (31)

1. von Bohlen und Halbach O, Schober A, Krieglstein K: Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 2004;73:151-177.
2. Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
3. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN: Nigral and extranigral pathology in Parkinson's disease. J Neural Transm 1995;46(suppl):15-31.
4. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K: Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493-500.
5. Jellinger KA: Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl 1997;51:57-82.
6. Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M: Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 1999;45:601-610.
7. Benke T, Bosch S, Andree B: A study of emotional processing in Parkinson's disease. Brain Cogn 1998;38:36-52.
8. Pell MD: On the receptive prosodic loss in Parkinson's disease. Cortex 1996;32:693-704.
9. Borod JC, Welkowitz J, Alpert M, Brozgold AZ, Martin C, Peselow E, Diller L: Parameters of emotional processing in neuropsychiatric disorders: Conceptual issues and a battery of tests. J Commun Disord 1990;23:247-271.
10. LeDoux JE: Emotional memory: In search of systems and synapses. Ann NY Acad Sci 1993;702:149-157.
11. Rolls ET: Memory systems in the brain. Annu Rev Psychol 2000;51:599-630.
12. Braak H, Braak E: Pathoanatomy of Parkinson's disease. J Neurol 2000;247(suppl 2):II3-II10.
13. Kahle PJ, Haass C, Kretzschmar HA, Neumann M: Structure/function of alpha-synuclein in health and disease: Rational development of animal models for Parkinson's and related diseases. J Neurochem 2002;82:449-457.
14. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J, Ruberg M, Prigent A, Cohen-Salmon C, Launay JM: Animal models of Parkinson's disease in rodents induced by toxins: An update. J Neural Transm Suppl 2003;65:89-100.
15. Speciale S: MPTP: Insights into parkinsonian neurodegeneration. Neurotoxicol Teratol 2002;24:607-620.
16. Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-224.
17. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M: The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
18. Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001;125:109-125.
19. Hung HC, Lee EH: The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: Role of BDNF gene expression. Brain Res Mol Brain Res 1996;41:14-26.
20. Schmidt N, Ferger B: Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001;108:1263-1282.
21. Otto D, Unsicker K: Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990;10:1912-1921.
22. Mamounas LA, Altar CA, Blue ME, Kaplan DR, Tessarollo L, Lyons WE: BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 2000;20:771-782.
23. von Bohlen und Halbach O, Unsicker K: Age-related decline in the tyrosine hydroxylase-immunoreactive innervation of the amygdala and dentate gyrus in mice. Cell Tissue Res 2003;311:139-143.
24. De Olmos JE, Alheid GF, Beltramino CA: Amygdala; in Paxinos G (ed): The Rat Nervous System. Sydney, Academic Press, 1985, pp 223-334.
25. Huang CC, Lee EH: Alteration of corticotropin-releasing factor immunoreactivity in MPTP-treated rats. J Neurosci Res 1995;41:471-480.
26. Cohen RM, Carson RE, Aigner TG, Doudet D.J.: Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Res 1998;806:292-296.
27. Cole DG, Growdon JH, DiFiglia M: Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Exp Neurol 1993;120:223-232.
28. Chen Q, Andersen AH, Zhang Z, Ovadia A, Cass WA. Gash DM, Avison MJ: Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Exp Neurol 1999;158:63-75.
29. Dujardin K, Blairy S, Defebvre L, Duhem S, Noel Y, Hess U, Destee A: Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia 2004;42:239-250.
30. Kan Y, Kawamura M, Hasegawa Y, Mochizuki S, Nakamura K: Recognition of emotion from facial, prosodic and written verbal stimuli in Parkinson's disease. Cortex 2002;38:623-630.
31. Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, Weinberger DR, Mattay VS: Dopamine modulates the response of the human amygdala: A study in Parkinson's disease. J Neurosci 2002;22:9099-9103.